CORDIS Project

Clinical safety, immunogenicity and efficacy of a therapeutic vaccine that combines peptides mimicking antigen receptors on autoimmune B and T cells associated with myasthenia gravis

Myasterix·602420·FP7

Funding breakdown and partner intelligence are Premium

Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1

Upgrade

Start free • Cancel anytime • 14-day refund guarantee

View on CORDIS

Funding data

Programme: FP7
Participants: 4
Start - End: 01/10/2013 — 30/09/2018
Status: CLOSED

Summary

The MYASTERIX project aims to develop a therapeutic vaccine for myasthenia gravis, an autoimmune disease that causes muscle weakness. The vaccine uses synthetic peptides to generate antibodies that target the disease's underlying mechanisms, showing promising results in animal models and aiming for clinical trials to a…

Full AI summary and premium intelligence

Upgrade to Premium for the complete AI summary, similar projects, consortium analytics, OpenAlex context, and funding breakdown.

Upgrade Sign in

Start free • Cancel anytime • 14-day refund guarantee

Objective

The MYASTERIX project will advance a therapeutic vaccine candidate (designated orphan drug) indicated for the autoimmune disease myasthenia gravis (MG) to clinical proof of concept studies. MG is caused by T cell dependent antibodies that bind to and deplete acetylcholine receptors (AChR) at neuromuscular junctions causing muscle weakness by interfering with neuromuscular transmission and junction architecture.

The vaccine candidate comprises two synthetic peptides designed to generate antibodie…

Full objective and premium intelligence

Upgrade to Premium for the complete objective, AI summary, similar projects, consortium analytics, OpenAlex context, and funding breakdown.

Upgrade Sign in

Start free • Cancel anytime • 14-day refund guarantee

Coordinator

INSERM TRANSFERT SA

Country: France, PARIS
Organization type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No

Network and participants(4 participants)

Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.

CURAVAC
Belgium, RIXENSART
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
participant
PiCHEM
Austria, Raaba-Grambach
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
participant
Leiden University Medical Center
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
participant
AEPODIA
Belgium, OTTIGNIES LOUVAIN LA NEUVE
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
participant

4 participants shown of 6

Upgrade Sign in

Start free • Cancel anytime • 14-day refund guarantee

Partner & research intelligence

Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.

Consortium analytics and research context are Premium

Upgrade Sign in

Start free • Cancel anytime • 14-day refund guarantee

CORDIS call / funding scheme

Call: —
Sub call: FP7-HEALTH-2013-INNOVATION-1
Funding scheme: CP-FP - Small or medium-scale focused research project
Domain note: This block describes the CORDIS project call context. Live open opportunities are managed in the Funding & Tenders domain.

Fields of Science (EuroSciVoc)

Guests see up to 5 EuroSciVoc fields.

Medical and health sciencesBasic medicineToxicology

Topic

Guests see up to 5 topics.

HEALTH.2013.1.3-3

Sector

Guests see up to 5 sectors.

Health & Biotech